



Dear Members of the FXS Community,

On behalf of all of us at Harmony Biosciences, I want to share some news with you. Earlier today we announced that the Phase 3 RECONNECT study did not meet its primary endpoint. I know this is not the news any of us hoped for. It is disappointing, and I want to take a moment to acknowledge the years of effort, perseverance, and hope that went into this program.

This journey started with Zynherba Pharmaceuticals and continued at Harmony Biosciences because of the unmet needs in FXS. I am deeply grateful to the families, caregivers, clinicians, and researchers who participated in the study. I know the commitment required to be part of clinical research is significant, and your willingness to step forward made this work possible.

While the outcome is not what we wanted, this research adds important knowledge that will inform the field and future research in FXS. On behalf of all of us at Harmony, thank you for your trust, your resilience, and your partnership.

Best regards,

A handwritten signature in black ink, which appears to read 'Dr. David J. Reiss'.